Abiomed (BMV:ABMD *) - Stock Price, News & Analysis

ABMD * Stock Overview

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart.

About the company

ABMD * fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	1/6
Past Performance	4/6
Financial Health	6/6
Dividends	0/6

Rewards

Revenue is forecast to grow 14.15% per year

Earnings grew by 78.9% over the past year

Risk Analysis

Earnings are forecast to decline by an average of 2.5% per year for the next 3 years

Shares are highly illiquid

Large one-off items impacting financial results

Abiomed, Inc. Competitors

Sonova Holding

SWX:SOON

CHF15.2b

Olympus

TSE:7733

JP¥2.5t

Cochlear

ASX:COH

AU$21.1b

STERIS

NYSE:STE

US$20.4b

Price History & Performance

Summary of all time highs, changes and price drops for Abiomed
Historical stock prices
Current Share Price	US$7,565.00
52 Week High	US$7,565.00
52 Week Low	US$4,642.00
Beta	1.4
1 Month Change	4.12%
3 Month Change	n/a
1 Year Change	6.22%
3 Year Change	130.18%
5 Year Change	n/a
Change since IPO	46.84%

Recent updates

Shareholder Returns

	ABMD *	MX Medical Equipment	MX Market
7D	0%	0%	0%
1Y	6.2%	0%	0%

Return vs Industry: ABMD * exceeded the MX Medical Equipment industry which returned -2.1% over the past year.

Return vs Market: ABMD * exceeded the MX Market which returned 3.7% over the past year.

Price Volatility

Is ABMD *'s price volatile compared to industry and market?
ABMD * volatility
ABMD * Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in MX Market	0%
10% least volatile stocks in MX Market	0%

Stable Share Price: ABMD *'s share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine ABMD *'s volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1981	2,003	Mike Minogue	www.abiomed.com

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite.

Abiomed, Inc. Fundamentals Summary

How do Abiomed's earnings and revenue compare to its market cap?
ABMD * fundamental statistics
Market cap	Mex$335.38b
Earnings (TTM)	Mex$5.21b
Revenue (TTM)	Mex$20.96b

64.4x

P/E Ratio

16.0x

P/S Ratio

Is ABMD * overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ABMD * income statement (TTM)
Revenue	US$1.07b
Cost of Revenue	US$200.59m
Gross Profit	US$873.51m
Other Expenses	US$606.74m
Earnings	US$266.76m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	5.91
Gross Margin	81.32%
Net Profit Margin	24.84%
Debt/Equity Ratio	0%

How did ABMD * perform over the long term?

See historical performance and comparison

ABMD * Stock Overview

Rewards

Risk Analysis

Abiomed, Inc. Competitors

SWX:SOON

CHF15.2b

TSE:7733

JP¥2.5t

ASX:COH

AU$21.1b

NYSE:STE

US$20.4b

Price History & Performance

Recent News & Updates

Abiomed to Highlight Data Analysis Identifying Complex Clinical Profile of Patients Receiving Impella-Supported HRPCI at TCT Symposium

Johnson & Johnson (NYSE:JNJ) completed the acquisition of Abiomed, Inc. (NasdaqGS:ABMD).

Abiomed Announces United States Food and Drug Administration Approves Version of Impella ECP

Abiomed, Inc.(NasdaqGS:ABMD) dropped from FTSE All-World Index (USD)

Abiomed, Inc. Announces First Patients in the World Treated with Impella Rp Flex with Smartassist

Johnson & Johnson (NYSE:JNJ) entered into a definitive agreement to acquire Abiomed, Inc. (NasdaqGS:ABMD) for $17.4 billion.

Recent updates

Abiomed to Highlight Data Analysis Identifying Complex Clinical Profile of Patients Receiving Impella-Supported HRPCI at TCT Symposium

Johnson & Johnson (NYSE:JNJ) completed the acquisition of Abiomed, Inc. (NasdaqGS:ABMD).

Abiomed Announces United States Food and Drug Administration Approves Version of Impella ECP

Abiomed, Inc.(NasdaqGS:ABMD) dropped from FTSE All-World Index (USD)

Abiomed, Inc. Announces First Patients in the World Treated with Impella Rp Flex with Smartassist

Johnson & Johnson (NYSE:JNJ) entered into a definitive agreement to acquire Abiomed, Inc. (NasdaqGS:ABMD) for $17.4 billion.

Impella RP Flex with SmartAssist Receives FDA Approval to Treat Right Heart Failure

Abiomed, Inc. Successfully Completes All Impella Post-Approval Studies for High-Risk PCI, Cardiogenic Shock, Post-Cardiotomy Cardiogenic Shock and Right Heart Failure

The United States Food and Drug Administration Grants 510(k) Clearance for Impella Low Profile Sheath

Abiomed, Inc. to Report Q2, 2023 Results on Nov 01, 2022

Abiomed Announces Two Approvals from the U.S. Food and Drug Administration Related to Clinical Research of Impella Heart Pumps in Acute Myocardial Infarction Cardiogenic Shock Patients

Abiomed Announces Restore EF Study Shows Heart Function, Symptom Improvements for High-Risk PCI Patients Supported by Impella

First quarter 2023 earnings released: EPS: US$1.20 (vs US$0.58 loss in 1Q 2022)

Abiomed, Inc. (NasdaqGS:ABMD) announces an Equity Buyback for $200 million worth of its shares.

Abiomed, Inc. to Report Q1, 2023 Results on Aug 04, 2022

Abiomed, Inc., Annual General Meeting, Aug 10, 2022

Full year 2022 earnings released: EPS: US$3.00 (vs US$5.00 in FY 2021)

Full year 2022 earnings released: EPS: US$3.00 (vs US$5.00 in FY 2021)

Abiomed, Inc. to Report Q4, 2022 Results on Apr 28, 2022

Abiomed, Inc. Announces Retirement of David Weber as Senior Vice President, Chief Operating Officer

Independent Director recently sold Mex$24m worth of stock

Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Abiomed, Inc. Revises Revenue Guidance for the Fiscal Year 2022

Early Feasibility Study Demonstrates Successful Use of Abiomed’s preCARDIA Technology

Abiomed, Inc. Announces Regulators Grants Approvals for Impella Surgical Products

Abiomed, Inc. (NasdaqGS:ABMD) agreed to acquire all the assets and business from Sensera, Inc. for $7.5 million.

Independent Director recently sold Mex$105m worth of stock

Second quarter 2022 earnings released: EPS US$1.25 (vs US$1.38 in 2Q 2021)

First quarter 2022 earnings released: EPS US$1.38 (vs US$0.99 in 1Q 2021)

Abiomed’s Receives U.S. Food and Drug Administration Pre-Market Approval as Safe and Effective to Treat Acute Right Heart Failure for Up to 14 Days

Abiomed, Inc. (NasdaqGS:ABMD) acquired Precardia Inc.

Full year 2021 earnings released: EPS US$5.00 (vs US$4.49 in FY 2020)

Full year 2021 earnings released: EPS US$5.00 (vs US$4.49 in FY 2020)

Full year 2021 earnings released: EPS US$5.00 (vs US$4.49 in FY 2020)

Abiomed, Inc. Provides Earnings Guidance for the Fiscal Year 2022

Abiomed Appoints of Myron L. Rolle to its Board of Directors

Third quarter 2021 earnings released: EPS US$1.37 (vs US$1.53 in 3Q 2020)

New 90-day high: Mex$6,952

Revenue beats expectations

Third quarter 2021 earnings released: EPS US$1.37 (vs US$1.53 in 3Q 2020)

Revenue beats expectations

New 90-day high: Mex$6,473

Abiomed, Inc. to Report Q3, 2021 Results on Jan 28, 2021

New 90-day high: Mex$6,240

New 90-day low: Mex$5,276

New 90-day low: Mex$5,302

Revenue beats expectations

Second quarter 2021 earnings released: EPS US$1.38

Abiomed Announces FDA Grants 510(k) Clearance for the Company's Innovative Cardiopulmonary Support Technology

Abiomed, Inc. Announces New Protect Iii Study Data That Demonstrates Reduced Rates of MACCE

Abiomed, Inc. to Report Q2, 2021 Results on Oct 29, 2020

Abiomed, Inc. Not to Provide Earnings Guidance for the Fiscal Year 2021

First quarter earnings released

Abiomed, Inc. (NasdaqGS:ABMD) acquired the remaining stake in Breethe, Inc.

Abiomed, Inc. to Report Q1, 2021 Results on Aug 06, 2020

Shareholder Returns

Price Volatility

About the Company

Abiomed, Inc. Fundamentals Summary